Deregulation of folate pathway gene expression correlates with poor prognosis in acute leukemia
- Jorge Organista‑Nava
- Yazmín Gómez‑Gómez
- Oscar del Moral‑Hernandez
- Berenice Illades‑Aguiar
- Jazmin Gómez‑Santamaria
- Ana Bertha Rivera‑Ramírez
- Mónica Virginia Saavedra‑Herrera
- Marco Antonio Jimenez‑López
- Marco Antonio Leyva‑Vázquez
Published online on: July 22, 2019
Copyright: © Organista‑Nava et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
| PMC Statistics:
Total PDF Downloads:
| PMC Statistics:
The present study analyzed the mRNA expression levels of genes involved in the transport and metabolism of methotrexate (MTX) (RFC1, ABCC1, ABCB1, GGH, FPGS, ATIC, TS, MTHFR, MTRR, MS and MTHFD1) in patients with acute leukemia (AL). The expression levels of the examined genes were analyzed by reverse transcription quantitative polymerase chain reaction (RT‑qPCR) in patients with AL (ALL:50/AML:19) and 66 healthy individuals. The mRNA expression levels of RFC1, MS, MTRR, MTHFR and ABCB1 were decreased (P<0.05), while those of GGH, FPGS, TS and MTHFD1 (P<0.05) were overexpressed in patients with AL. Patients with high mRNA levels of GGH (OR=4.28, 95% CI=1.29‑14.14), TS (OR=7.14, 95% CI 1.84‑27.81), MTHFR (OR=4.81, 95% CI=1.31‑17.64), ABCB1 (OR=4.61, 95% CI=1.33‑15.97) and ABCC1 (OR=5.50, 95% CI=1.12‑27.06) had a higher chance of relapse. Interestingly, high mRNA levels of RFC1 are a protective factor in the risk of AL relapse (OR=0.22, 95% 0.06‑0.80). The results of the present study indicated that deregulation of folate pathway gene expression is associated with poor prognosis in AL and that the expression levels of these markers could serve as novel molecular targets for the treatment of patients with AL.